EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Myeloperoxidase to Reduce Neuroinflammation in X‐Linked Dystonia Parkinsonism

Tiziana Petrozziello, Negin Jalali Motlagh, Ranee Zara B Monsanto, Dan Lei, Micaela G Murcar, Ellen B Penney, D Cristopher Bragg, Cara Fernandez-Cerado, G Paul Legarda, Michelle Sy, Edwin Muñoz, Mark C Ang und 6 weitere

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Tiziana Petrozziello und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Peroxidase, Genetic Diseases, X-Linked, Dystonic Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Ellison Foundation, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although the genetic locus of X‐linked dystonia parkinsonism (XDP), a neurodegenerative disease endemic in the Philippines, is well‐characterized, the exact mechanisms leading to neuronal loss are not yet fully understood. Recently, we demonstrated an increase in myeloperoxidase (MPO) levels in XDP postmortem prefrontal cortex (PFC), suggesting a role for inflammation in XDP pathogenesis. Therefore, we hypothesized that inhibiting MPO could provide a therapeutic strategy for XDP.

Methods

MPO activity was measured by using an MPO‐activatable fluorescent agent (MAFA) in human postmortem PFC. Reactive oxygen species (ROS) and MPO activity were measured in XDP‐derived fibroblasts and SH‐SY5Y cells following MPO inhibition.

Results

MPO activity was significantly increased in XDP PFC. Additionally, treatment of cell lines with postmortem XDP PFC resulted in a significant increase in ROS levels. To determine whether increases in MPO activity caused increases in ROS, MPO content was immunodepleted from XDP PFC, which resulted in a significant decrease in ROS in SH‐SY5Y cells. Consistently, the treatment with verdiperstat, a potent and selective MPO inhibitor, significantly decreased ROS in both XDP‐derived fibroblasts and XDP PFC‐treated SH‐SY5Y cells.

Conclusions

Collectively, our results suggest that MPO inhibition mitigates oxidative stress and may provide a novel therapeutic strategy for XDP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesPeroxidaseGenetic Diseases, X-LinkedDystonic DisordersHumansNeuroinflammatory DiseasesPrefrontal CortexMaleCell Line, TumorFibroblastsMiddle AgedFemalePiperidines

Stichwörter der Autor:innen

X‐linked dystonia parkinsonisminflammationmyeloperoxidaseverdiperstat

Substanzen

Reactive Oxygen SpeciesPeroxidaseMPO protein, humanPiperidines

Autor:innen und Institutionen

  • Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Radiology, Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Sunshine Care Foundation, Roxas City, Capiz, Philippines.

ORCID-Profile: Ghazaleh Sadri-Vakili

Förderung

  • NIH HHS
  • Ellison Foundation
  • NIA NIH HHS
  • NINDS NIH HHS
  • Collaborative Center for X-linked dystonia parkinsonism (CCXDP) at Massachusetts General Hospital
  • National Institutes of Health

Zitieren

APA

Petrozziello, T., Motlagh, N. J., Monsanto, R. Z. B., Lei, D., Murcar, M. G., Penney, E. B., Bragg, D. C., Fernandez-Cerado, C., Legarda, G. P., Sy, M., Muñoz, E., Ang, M. C., Diesta, C. C. E., Zhang, C., Tanzi, R. E., Qureshi, I. A., Chen, J. W., & Sadri-Vakili, G. (2024). Targeting Myeloperoxidase to Reduce Neuroinflammation in X‐Linked Dystonia Parkinsonism. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70109

Vancouver

Petrozziello T, Motlagh NJ, Monsanto RZB, Lei D, Murcar MG, Penney EB, et al. Targeting Myeloperoxidase to Reduce Neuroinflammation in X‐Linked Dystonia Parkinsonism. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70109

BibTeX
@article{Petrozziello2024,
  author = {Petrozziello, Tiziana and Motlagh, Negin Jalali and Monsanto, Ranee Zara B and Lei, Dan and Murcar, Micaela G and Penney, Ellen B and Bragg, D Cristopher and Fernandez-Cerado, Cara and Legarda, G Paul and Sy, Michelle and Muñoz, Edwin and Ang, Mark C and Diesta, Cid Czarina E and Zhang, Can and Tanzi, Rudolph E and Qureshi, Irfan A and Chen, John W and Sadri-Vakili, Ghazaleh},
  title = {Targeting Myeloperoxidase to Reduce Neuroinflammation in X‐Linked Dystonia Parkinsonism},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.70109}
}
Kostenlos starten →